MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
about
Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.Differential diagnosis of neuromyelitis optica spectrum disorders.Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination.Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy.Diffusion tensor imaging for multilevel assessment of the visual pathway: possibilities for personalized outcome prediction in autoimmune disorders of the central nervous system.Pediatric Optic Neuritis: What Is New.Pattern Recognition of the Multiple Sclerosis Syndrome.Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.Clinical characteristics of myelin oligodendrocyte glycoprotein seropositive optic neuritis: a cohort study in Shanghai, China.Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures.Mechanisms for lesion localization in neuromyelitis optica spectrum disorders.[Optical coherence tomography in neuromyelitis optica spectrum disorders].Defining distinct features of anti-MOG antibody associated central nervous system demyelination.MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder.The clinical features, underlying immunology, and treatment of autoantibody-mediated movement disordersCSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders
P2860
Q33645795-7FD425AA-9F49-4BC2-ABBE-72295B300FC3Q33812063-9D782EA3-A7E1-4AF2-A582-08640F655105Q33831179-34C5C888-C9C2-4B68-921B-E0CFA99499D4Q40066335-78A21FC5-8298-4BD3-8633-174C9BF32724Q41570018-3E1D931F-0D5E-4A08-96D6-0FE03CCB957AQ42361527-517E5CE9-748B-4808-B82D-D9F93769424CQ44434614-93C05C3B-6FDD-44D8-9D3E-7E21171D96CAQ47096340-68762A3F-1B6E-47D2-AD81-268110630E1FQ47163794-549BC7B0-37F4-44EF-A14B-5D98DF798362Q47284937-0879465C-FD9C-49A2-B7F6-43AC4361229AQ47581499-E83574CA-7FF7-43F2-AAF9-6E0296649377Q47987707-8202BD86-8175-4795-BAED-4B201133675EQ49204844-09845178-55B4-4CD9-AB1A-BE41B0C63DD4Q49713173-4AFFAEDF-88F7-4DB3-A0E6-89BA1A8EF31DQ50101454-9215B237-4EAC-4607-BC6D-AC9CD4A90940Q52603606-3C8BBE39-0EB8-430E-8239-9826BC6736EDQ52648377-37AFEA9F-ED40-460B-9FAE-BA925B680ABEQ52803391-A1E01D7F-D4EE-4835-896A-917112AC4B77Q55221002-1A1858F1-2930-49E1-8B6B-097A1FBF54DBQ57157350-D6B38355-4FBB-43A2-9B1F-C67C63C314C4Q58698171-C4636C5A-94DE-4FF3-A5DA-7F5E51004F09
P2860
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
MOG-IgG in NMO and related dis ...... ncy, presentation and outcome.
@en
MOG-IgG in NMO and related dis ...... ncy, presentation and outcome.
@nl
type
label
MOG-IgG in NMO and related dis ...... ncy, presentation and outcome.
@en
MOG-IgG in NMO and related dis ...... ncy, presentation and outcome.
@nl
prefLabel
MOG-IgG in NMO and related dis ...... ncy, presentation and outcome.
@en
MOG-IgG in NMO and related dis ...... ncy, presentation and outcome.
@nl
P2093
P2860
P50
P1476
MOG-IgG in NMO and related dis ...... ncy, presentation and outcome.
@en
P2093
Alexander Schwarz
Alexander U Brandt
Alexander Winkelmann
Brigitte Wildemann
Carsten Lukas
Corinna Trebst
Diego Franciotta
Florence Pache
Friedemann Paul
Hanna Zimmermann
P2860
P2888
P356
10.1186/S12974-016-0719-Z
P577
2016-11-01T00:00:00Z
P6179
1052479369